Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499257 | 0.88 | PRMT5 (0.38) | CNR1CNR2PRMT5TLR2DRD2 | |
| SCHEMBL6496378 | 0.83 | ITGB3 (0.42) | CNR1CNR2PRMT5TLR2DRD2 | |
| SCHEMBL6499974 | 0.82 | ITGB3 (0.43) | CNR1CNR2PRMT5TLR2DRD2 | |
| SCHEMBL7464402 | 0.82 | CNR1 (0.44) | CNR1CNR2PRMT5TLR2DRD2 | |
| SCHEMBL6503934 | 0.81 | ITGB3 (0.42) | CNR1CNR2PRMT5TLR2DRD2 | |
| SCHEMBL381720 | 0.79 | ITGB3 (0.43) | PRMT5DRD2DRD3ITGB3ITGAV | |
| SCHEMBL6499264 | 0.77 | ITGAV (0.49) | ITGB3ITGAVITGA2B | |
| SCHEMBL6499934 | 0.76 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL382401 | 0.75 | ITGB3 (0.46) | PRMT5WDR77ITGB3ITGAVITGA2B | |
| SCHEMBL6496334 | 0.75 | CNR1 (0.43) | CNR1CNR2DRD2DRD3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | CNR1 446/4885CNR2 681/4885PRMT5 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.